---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-164040"
form_type: "8-K"
ticker: "KLRA"
cik: "0002096997"
company_name: "Kailera Therapeutics, Inc."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:23:54.737561+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kailera Therapeutics closes IPO raising $718.8M; issues 44.9M shares at $16.00

## Summary
- Closed IPO of 44,921,875 shares at $16.00 per share, including full exercise of underwriters' option for 5,859,375 additional shares.
- Gross proceeds of $718.8 million before underwriting discounts and offering expenses.
- Amended certificate of incorporation: authorized 800M shares of common stock and 10M shares of undesignated preferred stock.
- Adopted classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.
- Amended bylaws to require advance notice for stockholder proposals and director nominations, and limit action by written consent.

## SEC filing metadata
- accession: 0001193125-26-164040
- form_type: 8-K
- ticker: KLRA
- cik: 0002096997
- company_name: Kailera Therapeutics, Inc.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/d137434d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-164040
- JSON: https://secwatch.observer/filing/0001193125-26-164040.json
- Plain text: https://secwatch.observer/filing/0001193125-26-164040.txt

## Source-grounded claims
- claim_id: 4155bd13189cc843ab47d9dad5700997e7fa77f8
  claim: Kailera Therapeutics, Inc.: Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums (effective 2026-04-20).
  evidence_excerpt: On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm
- claim_id: 576b1f2b897b05910763691e7575a49fd2a16275
  claim: Kailera Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments (effective 2026-04-20).
  evidence_excerpt: On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.